Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research report released on Wednesday. The firm issued an outperform rating and a $605.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on the stock. Canaccord Genuity raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and increased their price objective for the company from $375.00 to $484.00 in a research report on Friday, May 5th. Vetr lowered shares of Regeneron Pharmaceuticals from a buy rating to a hold rating and set a $408.86 price objective for the company. in a research report on Monday, May 1st. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Tuesday, July 4th. Piper Jaffray Companies increased their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an overweight rating in a research report on Tuesday, June 20th. Finally, BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a hold rating in a research report on Monday, May 15th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of Hold and an average target price of $495.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.05% during mid-day trading on Wednesday, reaching $463.61. 95,300 shares of the company’s stock were exchanged. The company’s 50-day moving average is $492.11 and its 200 day moving average is $429.80. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The firm has a market capitalization of $49.16 billion, a P/E ratio of 46.51 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s revenue was up 21.2% on a year-over-year basis. During the same period last year, the firm posted $2.82 EPS. Equities analysts predict that Regeneron Pharmaceuticals will post $14.84 earnings per share for the current fiscal year.

WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Coverage Initiated by Analysts at Evercore ISI” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/17/regeneron-pharmaceuticals-inc-regn-coverage-initiated-by-analysts-at-evercore-isi.html.

In related news, SVP Robert E. Landry sold 526 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the sale, the senior vice president now directly owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the firm’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the sale, the chairman now directly owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,922 shares of company stock worth $27,383,105. Insiders own 10.40% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Regeneron Pharmaceuticals by 15,495.4% in the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after buying an additional 1,552,948 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares during the last quarter. Janus Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the last quarter. 67.16% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.